Перейти
на сайт журнала "Врач" |
Перейти на сайт журнала "Медицинская сестра"
|
Перейти на сайт журнала "Фармация"
|
Перейти на сайт журнала "Молекулярная медицина"
|
Перейти на сайт журнала "Вопросы биологической, медицинской и фармацевтической химии"
|
Журнал включен в российские и международные библиотечные и реферативные базы данных
ВАК (Россия)
|
РИНЦ (Россия)
|
Эко-Вектор (Россия)
|
DEVELOPMENT OF NASAL PHARMACEUTICAL PRODUCTS FOR SYSTEMIC EXPOSURE: USE OF PERMEATION ENHANCERS TO ACHIEVE TARGET PRODUCT PROFILE
DOI: https://doi.org/10.29296/25877313-2024-04-01
Issue:
4
Year:
2024
In recent years, special attention has been paid to non-invasive parenteral routes of administration, which are an alternative to injectable drugs, as well as other dosage forms whose effectiveness and safety may be compromised by the administration route. At the same time, there is a paradigm shift in relation to nasal dosage forms: they are no longer considered as primarily drugs exhibiting local effects, and an increasing number of nasal medici-nal products with systemic action are appearing on the market. There is a growing interest to the nasal delivery due to the possibility of maximizing the therapeutic potential of active substances that have proven themselves in clinical practice, for example, by quick targeted action to the site of the pathological process, increased bioavailability of the drug and reduced possible side effects. The nasal cavity as a site for systemic drug absorption has anatomical and physiological features that include a relatively large surface area, a porous endothelial basement membrane, a highly vascularized epithelial layer, high total blood flow, lack of first-pass metabolism, and easy access. Therefore, the development of a convenient (nasal) dosage form of the drug with a rapid onset of action is a promising approach. When developing a new pharmaceutical product, the factors that determine bioavaila-bility should be taken into account and addressed by appropriate formulation and delivery techniques: the use of mucoadhesive components or sub-stances that modulate mucociliary clearance, variation of the viscosity or osmolarity, or selection of an appropriate dosing device. Improving intrana-sal absorption is a promising direction for obtaining drugs with improved consumer properties. In addition to the functional properties of the formula-tions, safety aspects must also be taken into account. The article provides an analysis of the limiting factors for nasal preparations, strategies for in-creasing bioavailability, permeation enhancement mechanisms, and provides examples of the application of permeation enhancers used in developed and commercially available drugs. This review gives an idea on possible to use in nasal formulations permeation enhancers which have different mode of actions.
Keywords:
Nasal Sprays
Drug Compounding
Bioavailability
Permeation Enhancers
Excipients
Safety.
References:
- Thorat S. Formulation and Product Development of Nasal Spray: An Overview. Scholars Journal of Applied Medical Sciences (SJAMS). 2016;4(8D):2976–2985. DOI: 10.36347/sjams.2016.v04i08.048.
- Kim D., Kim Y.H., Kwon S. Enhanced nasal drug delivery efficien-cy by increasing mechanical loading using hypergravity. Scientific Reports. 2018;8(168). DOI: 10.1038/s41598-017-18561-x.
- Gizurarson S. The Effect of Cilia and the Mucociliary Clearance on Successful Drug Delivery. Biological and Pharmaceutical Bulle-tin. 2015;38(4):497–506. DOI: 10.1248/bpb.b14-00398.
- Luo D., Ni X., Yang H.et al. A comprehensive review of advanced nasal delivery: Specially insulin and calcitonin. European Journal of Pharmaceutical Sciences. 2024;192:106630. DOI: 10.1016/j.ejps.2023.106630.
- Bitter C., Suter-Zimmermann K., Surber C. Nasal drug delivery in humans. Curr Probl Dermatol. 2011;40:20–35. DOI: 10.1159/000321044.
- Moghimipour E., Ameri A., Handali S. Absorption-Enhancing Ef-fects of Bile Salts. Molecules. 2015 Aug 10;20(8):14451–14473. DOI: 10.3390/molecules200814451.
- Tai J., Han M., Lee D. et. al. Different Methods and For-mulations of Drugs and Vaccines for Nasal Administration. Pharmaceutics. 2022 May 17;14(5):1073. DOI: 10.3390/pharmaceutics14051073.
- Deli M.A. Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochimica et Biophysica Acta (BBA) – Biomembranes. 2009;1788(4):892–910. DOI: 10.1016/j.bbamem.2008.09.016.
- Chavanpatil M.D., Vavia P.R. The influence of absorption enhanc-ers on nasal absorption of acyclovir. Eur. J. Pharm. Biopharm. 2004;57(3):483–487. DOI: 10.1016/j.ejpb.2004.01.001.
- Kim I.W., Yoo H., Song I.S. et.al. Effect of excipients on the stabil-ity and transport of recombinant human epidermal growth factor (rhEGF) across CACO-2 cell monolayers. Arch. Pharm. Res. 2003;26(4):330–337. DOI: 10.1007/BF02976964.
- Amancha K.P., Hussain A. Effect of protease inhibitors on pulmo-nary bioavailability of therapeutic proteins and peptides in the rat. Eur. J. Pharm. Sci. 2015;68:1–10. DOI: 10.1016/j.ejps.2014.11.008.
- Ghadiri M., Canney F., Pacciana C. et.al. The use of fatty acids as absorption enhancer for pulmonary drug delivery. Int. J. Pharm. 2018;541:93–100. DOI: 10.1016/j.ijpharm.2018.02.027.
- Ghadiri M., Mamlouk M., Spicer P. et.al. Effect of polyunsaturated fatty acids (PUFAs) on airway epithelial cells' tight junction. Pulm. Pharmacol. Ther. 2016;40:30–38. DOI: 10.1016/j.pupt.2016.07.004.
- Li F., Yang X.L., Yang Y.A. et.al. Phospholipid complex as an ap-proach for bioavailability enhancement of echinacoside. Drug Dev. Ind. Pharm. 2015;41(11):1777–1784. DOI: 10.3109/03639045.2015.1004183.
- Chono S., Fukuchi R., Seki T., Morimoto K. Aerosolized liposomes with dipalmitoyl phosphatidylcholine enhance pulmonary insulin delivery. J. Control. Release. 2009;137(2):104–109. DOI: 10.1016/j.jconrel.2009.03.019.
- Benediktsdottir B.E., Gudjonsson T., Baldursson O., Masson M. N-alkylation of highly quaternized chitosan derivatives affects the paracellular permeation enhancement in bronchial epithelia in vitro. Eur. J. Pharm. Biopharm. 2014; 86(1):55–63. DOI: 10.1016/j.ejpb.2013.04.002.
- Yamada K., Odomi M., Okada N., Fujita T., Yamamoto A. Chi-tosan Oligomers as Potential and Safe Absorption Enhancers for Improving the Pulmonary Absorption of Interferon-α in Rats. J. Pharm. Sci.-US. 2005; 94(11):2432–2440. DOI: 10.1002/jps.20454.
- Yamamoto A., Yamada K., Muramatsu H., et.al. Control of pulmo-nary absorption of water-soluble compounds by various viscous vehicles. Int. J. Pharm. 2004;282(1-2):141–149. DOI: 10.1016/j.ijpharm.2004.06.008.
- Shimpi S., Chauhan B., Shimpi P. Cyclodextrins: Application in different routes of drug administration. Acta Pharm. 2005;55(2):139–156.
- Suzuki H., Kondoh M., Li X. et. al. A toxicological evaluation of a claudin modulator, the C-terminal fragment of Clostridium perfringens enterotoxin, in mice. Pharmazie. 2011;66(7):543–546. DOI: 10.1691/ph.2011.0365.
- Bagger M.A., Nielsen H.W., Bechgaard E. Nasal bioavailability of peptide T in rabbits: absorption enhancement by sodium glycocho-late and glycofurol. Eur J Pharm Sci. 2001;14(1):69–74. DOI: 10.1016/S0928-0987(01)00146-4.
- Li Y., Li J., Zhang X., Ding J., Mao S. Non-ionic surfactants as novel intranasal absorption enhancers: in vitro and in vivo character-ization. Drug Deliv. 2016;23(7):2272–2279. DOI: 10.3109/10717544.2014.971196.
- Del Vecchio G., Tscheik C., Tenz K. et.al. Sodium Caprate Transi-ently Opens Claudin-5-Containing Barriers at Tight Junctions of Epithelial and Endothelial Cells. Mol. Pharm. 2012;9:2523–2533. DOI: 10.1021/mp3001414.
- Sørli J.B., Balogh Sivars K., Da Silva E. et. al. Bile salt enhancers for inhalation: Correlation between in vitro and in vivo lung effects. Int. J. Pharm. 2018;550:114–122. DOI: 10.1016/j.ijpharm.2018.08.031.
- Schulz J.D., Gauthier M.A., Leroux J.C. Improving oral drug bioa-vailability with polycations? Eur. J. Pharm. Biopharm. 2015;97:427–437. DOI: 10.1016/j.ejpb.2015.04.025.
- Bayomi M.A., Abanumay K.A., Al-Angary A.A. Effect of inclusion complexation with cyclodextrins on photostability of nifedipine in solid state. Int J Pharm. 2002;243:107–117. DOI: 10.1016/S0378-5173(02)00263-6.
- Brewster M. E., Loftsson T. Cyclodextrins as pharmaceutical solu-bilizers. Advanced drug delivery reviews. 2007;59(7):645–666. DOI: 10.1016/j.addr.2007.05.012.
- Jassim Z.E., Al-Akkam E.J. A review on strategies for improving nasal drug delivery systems. Drug Invention Today. 2018;10:2857–2864.
- Natsheh H., Touitou E. Phospholipid Magnesome—a nasal vesicu-lar carrier for delivery of drugs to brain. Drug Deliv. Transl. Res. 2018;8:806–819. DOI: 10.1007/s13346-018-0503-y.
- Salama H.A., Mahmoud A.A., Kamel A.O. et. al. Characterization of fatty acid liposome coated with low-molecular-weight chitosan. J. Liposomal. Res. 2012;22:336–345. DOI: 10.3109/08982104.2012.700459.
- Salama H.A., Mahmoud A.A., Kamel A.O. et.al. Phospholipid based colloidal poloxamer–nanocubic vesicles for brain targeting via the nasal route. Colloids Surf. B Biointerfaces. 2012;100:146–154. DOI: 10.1016/j.colsurfb.2012.05.010.
- Aboud H.M., Ali A.A., El-Menshawe S.F., Elbary A.A. Nanotrans-fersomes of carvedilol for intranasal delivery: formulation, charac-terization and in vivo evaluation. Drug Deliv. 2016;23(7):2471–2481. DOI: 10.3109/10717544.2015.1013587.
- Mouez M.A., Nasr M., Abdel-Mottaleb M., Geneidi A.S., Mansour S. Composite chitosan-transfersomal vesicles for improved transna-sal permeation and bioavailability of verapamil. Int. J. Biol. Macro-mol. 2016;93:591–599. DOI: 10.1016/j.ijbiomac.2016.09.027.
- Naguib M.J., Salah S., Halim S.A.A., Badr-Eldin S.M. Investigating the potential of utilizing glycerosomes as a novel vesicular platform for enhancing intranasal delivery of lacidipine. Int J. Pharm. 2020;582:119302. DOI: 10.1016/j.ijpharm.2020.119302.
- Jones R.S. Conceptual Model for Using Imidazoline Derivative So-lutions in Pulpal Management. J. Clin. Med. 2021;10(6):1212. DOI: 10.3390/jcm10061212.
- Ruiz L., Aroche K., Reyes N. Aggregation of recombinant human interferon alpha 2b in solution: Technical note. AAPS PharmSciTech. 2006;7:99. DOI: 10.1208/pt070499.
- Moghadam S.H., Saliaj E., Wettig S.D. et al. Effect of Chemical Permeation Enhancers on Stratum Corneum Barrier Lipid Organiza-tional Structure and Interferon Alpha Permeability Molecular Phar-maceutics. 2013;10(6):2248–2260. DOI: 10.1021/mp300441c.
- Highlights of prescribing information Valtoco. Режим доступа: https://www.accessdata.fda.gov/drugsatfda_docs/ label/2020/211635s000lbl.pdf (дата обращения / accessed: 01.04.2024)
- Highlights of prescribing information Tosymra. Режим доступа: https://www.accessdata.fda.gov/drugsatfda_docs/la-bel/2019/210884s000lbl.pdf (дата обращения / accessed: 01.04.2024)
- Highlights of prescribing information Natesto. Режим доступа: https://www.accessdata.fda.gov/drugsatfda_docs/label/ 2014/205488s000lbl.pdf (дата обращения / accessed: 01.04.2024)
- Highlights of prescribing information Nayzilam. Режим доступа: https://www.accessdata.fda.gov/drugsatfda_docs/la-bel/2019/211321s000lbl.pdf (дата обращения / accessed: 01.04.2024)
- Highlights of prescribing information Noctiva. Режим доступа: https://www.accessdata.fda.gov/drugsatfda_docs/la-bel/2017/201656lbl.pdf (дата обращения / accessed: 01.04.2024)
- Highlights of prescribing information Baqsimi. Режим доступа: https://www.accessdata.fda.gov/drugsatfda_docs/la-bel/2019/210134s000lbl.pdf (дата обращения / accessed: 01.04.2024)
- EMA/CHMP/602404/2019. Режим доступа: https://www. ema.europa.eu/en/documents/assessment-report/baqsimiepar -public-assessment-report_en.pdf (дата обращения / accessed: 01.04.2024)